Glenmark Pharmaceuticals Ltd
GLENMARKGlenmark Pharmaceuticals Ltd
GLENMARK
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -48.13 | 5.37 | 0.17% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7,581.67 | 9,116.78 | 9,165.82 | 10,240.79 | 10,833.45 | 11,038.69 | 12,471.57 | 12,339.10 | 13,050.42 | 13,280.26 | ||||||||||
Raw Materials | 2,442.74 | 3,073.93 | 2,904.86 | 3,421.01 | 3,570.56 | 3,809.43 | 4,396.42 | 4,498.19 | 4,608.99 | 11,285.31 | ||||||||||
| Power & Fuel Cost | 120.47 | 127.02 | 137.48 | 165.26 | 173.69 | 164.67 | 200.64 | 111.75 | 124.00 | |||||||||||
| Employee Cost | 1,378.20 | 1,640.81 | 1,871.84 | 2,056.07 | 2,254.78 | 2,343.71 | 2,447.42 | 2,600.78 | 2,868.14 | |||||||||||
| Selling & Administrative Expenses | 1,395.79 | 1,589.86 | 1,523.27 | 1,750.21 | 1,667.02 | 1,453.55 | 1,543.27 | 1,752.30 | 1,708.60 | |||||||||||
| Operating & Other expenses | 787.32 | 692.04 | 1,021.60 | 887.12 | 1,276.84 | 1,088.19 | 1,657.76 | 1,751.06 | 2,208.99 | |||||||||||
EBITDA | 1,457.15 | 1,993.12 | 1,706.77 | 1,961.12 | 1,890.56 | 2,179.14 | 2,226.06 | 1,625.02 | 1,531.70 | 1,994.95 | ||||||||||
| Depreciation/Amortization | 234.28 | 264.37 | 301.88 | 325.91 | 417.17 | 443.55 | 486.72 | 569.17 | 581.91 | 536.49 | ||||||||||
| PBIT | 1,222.87 | 1,728.75 | 1,404.89 | 1,635.21 | 1,473.39 | 1,735.59 | 1,739.34 | 1,055.85 | 949.79 | 1,458.46 | ||||||||||
| Interest & Other Items | 178.89 | 237.32 | 285.57 | 334.59 | 377.32 | 353.11 | 298.10 | 349.04 | 515.97 | 370.96 | ||||||||||
| PBT | 1,043.98 | 1,491.43 | 1,119.32 | 1,300.62 | 1,096.07 | 1,382.48 | 1,441.24 | 706.81 | 433.82 | 1,087.50 | ||||||||||
| Taxes & Other Items | 300.94 | 382.67 | 315.46 | 375.63 | 320.11 | 412.44 | 499.54 | 409.56 | 1,935.49 | 1,962.66 | ||||||||||
| Net Income | 743.04 | 1,108.76 | 803.86 | 924.99 | 775.96 | 970.04 | 941.70 | 297.25 | -1,501.67 | -875.16 | ||||||||||
| EPS | 26.85 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | -31.01 | ||||||||||
| DPS | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | ||||||||||
| Payout ratio | 0.07 | 0.05 | 0.07 | 0.06 | 0.09 | 0.07 | 0.07 | 0.24 | — | -0.08 |
Company Updates
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | -28.05 | 5.37 | 0.17% |
| Sun Pharmaceutical Industries Ltd | 44.52 | 6.35 | 0.76% |
| Cipla Ltd | 28.83 | 4.43 | 0.88% |
| Torrent Pharmaceuticals Ltd | 63.23 | 15.28 | 0.90% |
Price Comparison
Compare GLENMARK with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.07%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Glenmark Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.2215% | Percentage of the fund’s portfolio invested in the stock 1.75% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 19/79 (+8) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1403% | Percentage of the fund’s portfolio invested in the stock 1.26% | Change in the portfolio weight of the stock over the last 3 months 0.64% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/105 (+15) |
Mirae Asset ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9254% | Percentage of the fund’s portfolio invested in the stock 1.57% | Change in the portfolio weight of the stock over the last 3 months 0.68% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/99 (+14) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
GLENMARK has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.17%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.67 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 13, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 13, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 12, 2022
Dividend/Share
₹2.50
Ex DateEx Date
Sep 12, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹2.50
Ex DateEx Date
Sep 17, 2020
Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1526.05, down 0.5% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.34% on the day, quoting at 23452.35. The Sensex is at 77362.6, down 0.28%.Glenmark Pharmaceuticals Ltd has eased around 11.11% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has eased around 6.32% in last one month and is currently quoting at 21752, down 0.42% on the day. The volume in the stock stood at 9.98 lakh shares today, compared to the daily average of 6.27 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1533.95, down 0.46% on the day. Glenmark Pharmaceuticals Ltd jumped 94.35% in last one year as compared to a 19.08% rally in NIFTY and a 37.04% spurt in the Nifty Pharma index.The PE of the stock is 26.72 based on TTM earnings ending June 24.Powered by Capital Market - Live
Revenue from operations increased 2.29% year on year (YoY) to Rs 3,133.79 crore in the quarter ended 30 September 2024. Profit before tax stood at Rs 472.57 crore in September 2024 quarter compared with pre-tax loss of Rs 124.35 crore posted in corresponding quarter previous year. EBITDA stood at Rs 601.9 crore in second quarter of FY25, registering a growth of 30.2% on YoY basis. During the quarter, EBITDA margin improved to 17.5% as against 14.4% in Q2 FY24. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The counter closed 0.44% lower at Rs 1,531.70 on Thursday, 14 November 2024. The stock market is closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live
Net profit of Glenmark Pharmaceuticals reported to Rs 354.21 crore in the quarter ended September 2024 as against net loss of Rs 81.95 crore during the previous quarter ended September 2023. Sales rose 7.59% to Rs 3400.50 crore in the quarter ended September 2024 as against Rs 3160.69 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3400.503160.69 8 OPM %17.7014.63 - PBDT592.85342.53 73 PBT472.57201.07 135 NP354.21-81.95 LP Powered by Capital Market - Live
Net profit of Glenmark Pharmaceuticals rose 96.81% to Rs 595.06 crore in the quarter ended September 2024 as against Rs 302.35 crore during the previous quarter ended September 2023. Sales rose 19.56% to Rs 2594.89 crore in the quarter ended September 2024 as against Rs 2170.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2594.892170.40 20 OPM %30.0120.43 - PBDT849.91458.89 85 PBT795.06409.04 94 NP595.06302.35 97 Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd gained for a third straight session today. The stock is quoting at Rs 1757.95, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.85% on the day, quoting at 24419.55. The Sensex is at 80155.08, up 0.85%. Glenmark Pharmaceuticals Ltd has gained around 4.95% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 0.45% in last one month and is currently quoting at 22661.25, up 0.94% on the day. The volume in the stock stood at 3.12 lakh shares today, compared to the daily average of 6.36 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1758, up 1.44% on the day. Glenmark Pharmaceuticals Ltd is up 131.57% in last one year as compared to a 25.83% jump in NIFTY and a 49.79% jump in the Nifty Pharma index.The PE of the stock is 30.09 based on TTM earnings ending June 24.Powered by Capital Market - Live
Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1712.1, up 2.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.43% on the day, quoting at 24901.55. The Sensex is at 81363.7, up 0.39%. Glenmark Pharmaceuticals Ltd has risen around 0.46% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 0.73% in last one month and is currently quoting at 22977.8, up 0.86% on the day. The volume in the stock stood at 5.12 lakh shares today, compared to the daily average of 12.48 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1720.2, up 2.22% on the day. Glenmark Pharmaceuticals Ltd is up 118.27% in last one year as compared to a 27.62% spurt in NIFTY and a 53.45% spurt in the Nifty Pharma index.The PE of the stock is 29.21 based on TTM earnings ending June 24.Powered by Capital Market - Live
The inspection was conducted from 9 September to 20 September 2024. In conclusion, the US Food and Drug Administration (USFDA) has issued Form 483 with zero observations. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live
The inspection was conducted from 9 September to 20 September 2024. In conclusion, the USFDA has issued Form 483 with zero observations. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. The scrip declined 1.56% to ends at Rs 1,625.40 on Friday, 20 September 2024. Powered by Capital Market - Live
Glenmark Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at the Company's formulation manufacturing facility based out of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9 September to 20 September, 2024. The inspection closed with no observationPowered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.97%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 4.67% to 3.46%